Profile http://med.stanford.edu/profiles/Andrew_Zolopa/ Email this page Printer friendly version

Key Documents

Andrew Zolopa

Associate Professor - Med Center Line, Medicine - Infectious Diseases

Contact Information

Clinical Offices

Positive Care Clinic 3801 Miranda Ave Bldg MB3 Ste 350 MC 5549 Palo Alto, CA 94304
Telephone Work (650) 354-8101 Fax (650) 354-8102

Clinical Focus

Infectious Disease
Infectious Diseases

Professional Education

SUMC - Graduate Medical Education (1992) CA
Board Certification: Internal Medicine, American Board of Internal Medicine (1988)
Santa Clara Valley Medical Center (1988) CA USA
Santa Clara Valley Medical Center (1985) CA USA
UCLA School of Medicine (1984) CA

Postdoctoral Advisees

Michael Gelman

Research Interests

Dr. Zolopa’s research applies a variety of clinical epidemiologic methods in an effort to optimize antiretroviral therapy and understand the impact of drug resistance on response to ARV. Areas of focus include the clinical application of resistance testing in optimizing antiretroviral therapy, clinical cohort and trials of antiretroviral therapies and population-based epidemiologic evaluation of HIV resistance and efficacy of ARV therapy in urban poor communities of San Francisco.

Clinical Trials

Publications

Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Grant P, Zolopa A. Curr HIV/AIDS Rep. 2009; 6 (2): 63-7
Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor. Grant P, Taylor J, Cain P, Short W, Gallant J, Farthing C, Thal G, Coakley E, Zolopa A. Clin Infect Dis. 2009; 48 (5): 680-2
Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. Haas DW, Koletar SL, Laughlin L, Kendall MA, Suckow C, Gerber JG, Zolopa AR, Bertz R, Child MJ, Hosey L, Alston-Smith B, Acosta EP. J Acquir Immune Defic Syndr. 2009; 50 (3): 290-3
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, Hogg E, Komarow L. PLoS One. 2009; 4 (5): e5575
Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations. Shahriar R, Rhee SY, Liu TF, Fessel WJ, Scarsella A, Towner W, Holmes SP, Zolopa AR, Shafer RW. Antimicrob Agents Chemother. 2009; 53 (11): 4869-78
Association of HIV Infection, Demographic and Cardiovascular Risk Factors With All-Cause Mortality in the Recent HAART Era. Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, Grunfeld C, Shlipak M, Tien PC. J Acquir Immune Defic Syndr. 2009;
Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study. DeJesus E, Gottlieb MS, Gathe JC, Greenberg ML, Guittari CJ, Zolopa AR. Antimicrob Agents Chemother. 2008; 52 (12): 4315-9
Integrase inhibitors: a clinical review of raltegravir and elvitegravir. Grant P, Zolopa A. J HIV Ther. 2008; 13 (2): 36-9
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores. Grant P, Wong EC, Rode R, Shafer R, De Luca A, Nadler J, Hawkins T, Cohen C, Harrington R, Kempf D, Zolopa A. Antimicrob Agents Chemother. 2008; 52 (11): 4050-6
Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, Degruttola V, Miller V, Costagliola D. J Infect Dis. 2008; 198 (4): 470-80
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Acosta EP, Kendall MA, Gerber JG, Alston-Smith B, Koletar SL, Zolopa AR, Agarwala S, Child M, Bertz R, Hosey L, Haas DW. Antimicrob Agents Chemother. 2007; 51 (9): 3104-10
Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet. Liu M, Holodniy M, Zolopa AR, Shafer RW. MedGenMed. 2006; 8 (1): 24
Incorporating drug-resistance measurements into the clinical management of HIV-1 infection. Zolopa AR, J Infect Dis. 2006; 194 Suppl 1 S59-64
N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW. AIDS Res Hum Retroviruses. 2006; 22 (12): 1300-5
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, Horberg M, Flamm J, Follansbee S, Schapiro JM, Shafer RW. J Infect Dis. 2005; 192 (3): 456-65
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study). Zolopa AR, Lazzeroni LC, Rinehart A, Vezinet FB, Clavel F, Collier A, Conway B, Gulick RM, Holodniy M, Perno CF, Shafer RW, Richman DD, Wainberg MA, Kuritzkes DR. Clin Infect Dis. 2005; 41 (1): 92-9
Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, Chou S, Zolopa AR, Fessel WJ, Shafer RW. AIDS. 2003; 17 (6): 791-9
Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation. Gonzales MJ, Delwart E, Rhee SY, Tsui R, Zolopa AR, Taylor J, Shafer RW. J Infect Dis. 2003; 188 (3): 397-405
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, Israelski D, Zolopa AR, Fessel WJ, Shafer RW. J Virol. 2003; 77 (8): 4836-47
Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boller S, Jiang P, Rode R, Gallant J, Race E, Kempf DJ, Sun E. Antimicrob Agents Chemother. 2002; 46 (12): 3907-16
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA. J Acquir Immune Defic Syndr. 2002; 31 (2): 121-7
Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Kantor R, Fessel WJ, Zolopa AR, Israelski D, Shulman N, Montoya JG, Harbour M, Schapiro JM, Shafer RW. Antimicrob Agents Chemother. 2002; 46 (4): 1086-92
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, Israelski DM, Hellmann N, Petropoulos C, Whitcomb J. AIDS. 2001; 15 (9): 1125-32
HIV drug resistance testing: an update for the clinician. Rice HL, Zolopa AR. AIDS Clin Care. 2001; 13 (10): 89-91, 94-6, 100
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. Shulman NS, Machekano RA, Shafer RW, Winters MA, Zolopa AR, Liou SH, Hughes M, Katzenstein DA. J Acquir Immune Defic Syndr. 2001; 27 (4): 377-80
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, Merigan TC, Harrigan R, Larder BA. J Clin Microbiol. 2001; 39 (4): 1522-9
Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells. Gray CM, Lawrence J, Ranheim EA, Vierra M, Zupancic M, Winters M, Altman J, Montoya J, Zolopa A, Schapiro J, Haase AT, Merigan TC. AIDS Res Hum Retroviruses. 2000; 16 (14): 1357-69
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. Shulman NS, Zolopa AR, Passaro DJ, Murlidharan U, Israelski DM, Brosgart CL, Miller MD, Van Doren S, Shafer RW, Katzenstein DA. J Acquir Immune Defic Syndr. 2000; 23 (3): 221-6
Invasive fungal sinusitis due to Scedosporium apiospermum in a patient with AIDS. Eckburg PB, Zolopa AR, Montoya JG. Clin Infect Dis. 1999; 29 (1): 212-3
Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Efron B, Winslow D, Merigan TC. J Infect Dis. 1999; 179 (6): 1356-64
HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B. Ann Intern Med. 1999; 131 (11): 813-21
Prevalence of measles antibodies in adults with HIV infection: possible risk factors of measles seronegativity. Kemper CA, Zolopa AR, Hamilton JR, Fenstersheib M, Bhatia G, Deresinski SC. AIDS. 1992; 6 (11): 1321-5